Drug class
Humanised monoclonal antibody fragment (scFv); vascular endothelial growth factor A (VEGF-A) inhibitor
Mechanism of action
Binds VEGF-A isoforms and prevents their interaction with VEGF receptors, reducing endothelial-cell proliferation, neovascularisation and vascular permeability in the retina.
General use cases
- Treatment of neovascular (wet) age-related macular degeneration (nAMD) in adults
- Treatment of diabetic macular oedema (DME) in adults where authorised by the relevant product label
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
